This paper studies the use of mycophenolate mofetil (MMF), an immunosuppressive medication, to treat severe atopic dermatitis. The researchers wanted to see if MMF could help reduce symptoms by blocking certain immune cell responses.
-
Treatment of atopic eczema with oral mycophenolate mofetil
Treatment of atopic eczema with oral mycophenolate mofetil
K Neuber, I Schwartz, G Itschert, A T Dieck
DOI: 10.1046/j.1365-2133.2000.03667.x
Controlled Clinical Trial
•
10 participants
•
2000
•
25 citations
-
What is this paper about?
-
How did the authors study this?
Ten patients were given MMF orally for 12 weeks. They started with 1g daily for the first week, then increased to 2g daily for the remaining 11 weeks. The researchers monitored disease severity using the SCORAD index and performed regular blood tests to check various immune markers and safety measures.
-
What populations did the authors study?
The study included 10 adult patients with severe atopic dermatitis, defined as having a SCORAD severity index greater than 5
-
What did the authors find?
All patients completed the study with no major side effects. Disease severity improved by 68% based on SCORAD measurements. Blood tests showed decreased IgE levels (from 10,300 to 7,830 kU L-1) and changes in immune markers, with an increase in IFN-gamma and decrease in IL-1
-
What conclusions can we draw?
The authors concluded that MMF at 2g daily is an effective, safe, and well-tolerated treatment for adults with severe atopic dermatitis. The medication showed promising results in reducing disease severity and changing immune responses.
